Curis Inc announced updated data from the ongoing TakeAim Leukemia study in relapsed/refractory Acute Myelogenous Leukemia to be presented at conferences.
AI Assistant
CURIS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.